Eli Lilly and Company has entered a strategic collaboration to co-develop Nektar Therapeutics’ new immunological therapy NKTR-358.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Having achieved the first human dose in Phase I clinical development in March this year, NKTR-358 can be used to treat a wide range of autoimmune and other chronic inflammatory conditions.
Discovered by Nektar Therapeutics, the treatment is a potential first-in-class resolution therapeutic that can address an underlying immune system imbalance in patients with several autoimmune conditions.
NKTR-358 targets the interleukin (IL-2) receptor complex in the patient’s body to stimulate proliferation of powerful inhibitory immune cells, known as regulatory T-cells.
The treatment is capable of activating these regulatory T-cells to bring the immune system back into balance, thereby resulting into healthy organ function in autoimmune conditions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNektar president and CEO Howard Robin said: “We are very pleased to enter into this collaboration with Lilly as they have strong expertise in immunology and a successful track record in bringing novel therapies to market.
“Importantly, this agreement enables the broad development of NKTR-358 in multiple autoimmune conditions in order to achieve its full potential as a first-in-class resolution therapeutic.”
Under the deal, Nektar Therapeutics will receive an initial payment of $150m and will be eligible for up to $250m in additional development and regulatory milestones.
The two companies will be jointly responsible for the manufacturing of NKTR-358, while Nektar will be responsible for completing the Phase I clinical development.
The Phase II development cost will be shared by both companies, with 75% investment from Lilly and the remaining 25% from Nektar Therapeutics.
In addition, Nektar will have the option to participate in Phase III development on an indication-by-indication basis.
Lilly will be responsible for all costs related to global commercialisation, while Nektar will have a provision to co-promote NKTR-358 in the US under certain conditions.
Image: Eli Lilly and Company's global headquarters, in Indianapolis, Indiana, US. Photo: courtesy of Guanaco152003 via Wikipedia.
